Setup

AnaptysBio (ANAB) completed the spin-off of its clinical-stage business (First Tracks Biotherapeutics / TRAX) on April 20, 2026. What remains is a pure royalty holding company with zero employees, a consulting CEO on a 9-month clock, and a board that just lost four directors. The filing's structural choices are consistent with a board contemplating a near-term acquisition.

What the filing says

Under the Separation Agreement, ANAB retained only the royalty streams: dostarlimab/Jemperli from GSK (tiered 8/12/20/25%, currently in the 12% bucket at $1.1B FY2025 sales) and imsidolimab from Vanda (flat 10% if approved, PDUFA December 12, 2026). All three clinical programs, $100M cash, and every employee moved to TRAX. The $35M in future Vanda milestones also went to TRAX — ANAB keeps only the annuity.

Four structural choices point the same direction:

• Distribution structured as a TAXABLE Section 301/311(b) distribution, not tax-free Section 355. Section 355(e) retroactively taxifies spins if the parent is acquired within 2 years — choosing taxable from the start eliminates that friction. A lawyer's drafting choice, not a tax-efficiency decision.
• CEO Dan Faga on a consulting agreement (not employment) through January 15, 2027, with accelerated vesting on early termination.
• Four board members resigned. CFO, CMO, and one other officer separated.
• ANAB has zero employees. Operates entirely via a Transition Services Agreement with TRAX.

Separately, the Sagard royalty obligation has ≈$350M remaining of a ≈$600M cap. Mechanical paydown from growing Jemperli royalties completes by ~Q4 2028, at which point ANAB's effective royalty rate on Jemperli steps up 2-3× as the waterfall stops diverting the top of the stack.

What the market thinks

On 29.44M shares outstanding, ANAB closed at $50.95 (+13.2% on the spin announcement) for a $1.5B market cap. Base standalone NPV works to ≈$1.4B, or ≈$47.55 per share. Bear NPV (GSK convenience termination): ≈$30. M&A base case (base NPV + 40% premium): ≈$75.

A simple three-state distribution with a 10% bear tail clears the current price at roughly:

10% bear ($30) + 70% standalone muddle ($47.55) + 20% upside ($75) ≈ $51

So the market is pricing roughly 10% bear / 70% muddle / 20% upside.

Sell-side consensus disagrees. Mean target $79.91 (+57%) implies 60-65% weight on the good outcome. Options corroborate the informed view: IV Rank 397%, P/C OI 0.14 (7× call skew), 30.8% short interest at 7.1 days to cover.

Our priors, in five non-overlapping scenarios: 55% M&A inside Faga's window to ≈$75 / 25% rerating-only drift to ≈$63 / 12% muddle at $50 / 8% bear to $30. Weighted expected value ≈$65, or +25-30% over a 9-14 month horizon. Probability ranges are honest: P(M&A) sits in a 40-65% band; the center is 55%, not a point estimate.

Why the gap exists

1. Forced sellers from the taxable distribution. Shareholders recognize FMV of TRAX shares as dividend income and sell ANAB or TRAX mechanically to fund tax. Supply unrelated to value.
2. Classification ambiguity. Biotech sector funds hold ANAB on mandates that no longer apply; royalty-aggregator funds haven't screened it yet. Reclassification takes 30-90 days.
3. Sell-side model lag. Analysts built forecasts around pipeline programs now owned by TRAX. Models refactor over 30-60 days; target revisions follow.

The Section 355(e) diagnostic is a legal-architecture signal, not a disclosure headline. Price and sell-side views diverge because the signal is in the exhibits, and the exhibits move slowly through the market.

Risks, ranked

1. GSK 90-day convenience termination on the Jemperli collaboration. No cause required. Would collapse ≈90% of NPV. Currently unlikely — Jemperli +89% YoY and GSK benefits from growth — but the biggest tail risk.
2. Standalone NPV is fair, not cheap. If the M&A thesis fails and rerating stalls, the floor is roughly where we are today. The asset alone does not compound.
3. ASO-1 dMMR rectal cancer readout (GSK, later 2026). A miss keeps Jemperli in the 12% tier and flatlines the bull case.
4. Faga consulting extended past January 15, 2027. Each extension materially weakens the M&A signal.
5. Dilutive secondary. Unlikely given the royalty cash-flow profile, but would falsify the thesis.

Catalysts

• May 5, 2026 — Q1 10-Q + earnings. First test of strategic-alternatives language. Cash position confirmation.
• Next 30-60 days — sell-side model refactoring window. Target revisions indicate whether $79.91 consensus holds.
• December 12, 2026 — Vanda imsidolimab PDUFA. Modest but positive if approved.
• Later 2026 — GSK ASO-1 rectal cancer readout. Tier step-up if positive.
• January 15, 2027 — Faga consulting agreement expires. Effective M&A deadline.
• ~Q4 2028 — Sagard obligation uncaps. Structural rerating independent of M&A.

What would change our mind

Toward bullish: 13D filing from Royalty Pharma, XOMA, HCR, or SWK; 8-K Item 1.01 merger agreement; explicit "strategic alternatives" language on May 5; Faga consulting terminated early with accelerated vesting firing; sell-side targets drifting above $80.

Toward bearish: GSK 90-day termination notice; Faga consulting extended without explanation; dilutive secondary; Q1 cash materially below $150M; ASO-1 rectal cancer readout fails; sell-side targets cut below $60.

Evidence

Bull

Bear / constraining

Foundational context